BioCentury | Dec 7, 2019
Product Development

U.S. biosimilars glass--half full or half empty?

...value certainty in supply and patient and provider services.” The launch of Ziextenzo, the Sandoz biosimilar pegfilgrastim...
BioCentury | Apr 5, 2019
Company News

Sandoz resubmits BLA for Neulasta biosimilar

...initial BLA in June 2016. Sandoz did not disclose what issues the agency raised (see "Biosimilar Pegfilgrastim...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...Zuprata Retinal vein occlusion (RVO) Top-line Ph III SAPPHIRE data 4Q18 Coherus BioSciences Inc. (NASDAQ:CHRS) Biosimilar pegfilgrastim...
BioCentury | Sep 28, 2018
Clinical News

CHMP backs Luxturna, Lilly's migraine mAb, antibiotic Vabomere

...drug Neulasta pegfilgrastim: Fulphila from Mylan N.V. (NASDAQ:MYL) and Biocon Ltd. (NSE:BIOCON; BSE:532523); Pelmeg from Infarco...
...South San Francisco, Calif. Mylan N.V. (NASDAQ:MYL), Canonsburg, Pa. Biocon Ltd. (NSE:BIOCON; BSE:532523), Bangalore, India Infarco...
...Jivi damoctocog alfa pegol, Poteligeo mogamulizumab, Cabometyx cabozantinib, Gilenya fingolimod, Fulphila biosimilar pegfilgrastim-jmdb, Pelmeg biosimilar pegfilgrastim, Ziextenzo biosimilar pegfilgrastim...
BioCentury | Sep 21, 2018
Company News

CHMP backs Luxturna, Lilly's migraine mAb, antibiotic Vabomere

...drug Neulasta pegfilgrastim: Fulphila from Mylan N.V. (NASDAQ:MYL) and Biocon Ltd. (NSE:BIOCON; BSE:532523); Pelmeg from Infarco...
...Other) Delstrigo, doravirine/lamivudine/tenofovir (MK-1439A) Emgality, galcanezumab (LY2951742) Exondys 51 (Brand), AVI-4658 (Compound #), eteplirsen (Generic), Exondys 51 (Other) Fulphila, biosimilar pegfilgrastim-jmdb...
...#), mogamulizumab (Generic), Poteligeo (Other) Vabomere (Brand), Carbavance (Former), meropenem/vaborbactam (Generic) Biocon Ltd. Camurus AB Eli Lilly and Co. Exelixis Inc. Infarco...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...rucaparib Metastatic castration-resistant prostate cancer (CRPC) Ph II TRITON2 data October Coherus BioSciences Inc. (NASDAQ:CHRS) Biosimilar pegfilgrastim...
BioCentury | Jun 25, 2018
Company News

CHMP interactions delaying Coherus biosimilar timeline

...Its BsUFA date is Nov. 3. Amgen Inc. (NASDAQ:AMGN) markets Neulasta, a pegylated G-CSF. Jaime De Leon biosimilar pegfilgrastim...
BioCentury | Jun 8, 2018
Clinical News

FDA approves first Neulasta biosimilar

...Bangalore, India Mylan N.V. (NASDAQ:MYL), Canonsburg, Pa. Product: Fulphila biosimilar pegfilgrastim-jmdb (MYL-1401H) Business: Hematology Elizabeth S. Eaton Fulphila, biosimilar pegfilgrastim-jmdb...
BioCentury | Jun 4, 2018
Company News

FDA approves first Neulasta biosimilar

...Rs655.20 on the National Stock Exchange, and rose Rs5.25 to Rs654.10 on the BSE. Elizabeth S. Eaton biosimilar pegfilgrastim...
BioCentury | May 23, 2018
Financial News

Coherus raises $75M in follow-on

...last year (see BioCentury Extra, June 12, 2017) . Pegfilgrastim is a pegylated G-CSF. Elizabeth S. Eaton biosimilar pegfilgrastim...
Items per page:
1 - 10 of 48